How to buy Novo Nordisk stock in Canada

Novo Nordisk is a drug manufacturers - general business based in the US. Novo Nordisk shares (NVO) are listed on the NYSE and all prices are listed in US Dollars.

Its last market close was $108.01 – a decrease of 3.29% over the previous week. Novo Nordisk employs 71,880 staff and has a trailing 12-month revenue of around $270.6 billion.

Our top picks for where to buy Novo Nordisk A/S stock

Buy Novo Nordisk A/S stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Novo Nordisk stock price (NYSE: NVO)

Use our graph to track the performance of NVO stocks over time.

Novo Nordisk stocks at a glance

• Key figures

Information last updated 2024-12-12.

Latest market close	$108.01
52-week range	$95.48 - $147.59
50-day moving average more info button	$118.58
200-day moving average more info button	$128.19
Wall St. target price	$941.31
PE ratio more info button	34.0268
Dividend yield more info button	$9.9 (1.42%)
Earnings per share (TTM) more info button	$2.99

Is it a good time to buy Novo Nordisk stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Novo Nordisk price performance over time

Historical closes compared with the close of $108.05 from 2024-12-16

1 week (2024-12-11)	-3.26%
1 month (2024-11-18)	8.26%
3 months (2024-09-18)	-18.18%
6 months (2024-06-18)	-23.26%

1 year (2023-12-18)	9.16%
2 years (2022-12-16)	66.14%
3 years (2021-12-17)	108.99%
5 years (2019-12-18)	311.61%

Is Novo Nordisk stock undervalued or overvalued?

Valuing Novo Nordisk stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Novo Nordisk's P/E ratio

Novo Nordisk's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Novo Nordisk shares trade at around 34x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

Novo Nordisk's PEG ratio

Novo Nordisk's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6614. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Novo Nordisk's EBITDA

Novo Nordisk's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $127.4 billion.

The EBITDA is a measure of a Novo Nordisk's overall financial performance and is widely used to measure a its profitability.

Novo Nordisk financials

Revenue TTM	$270.6 billion
Operating margin TTM	47.43%
Gross profit TTM	$148.5 billion
Return on assets TTM	21.47%
Return on equity TTM	88.73%
Profit margin	35.01%
Book value	$27.07
Market Capitalization more info button	$472.8 billion

TTM: trailing 12 months

Novo Nordisk stock dividends

Dividend payout ratio: 46.55% of net profits

Recently Novo Nordisk has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Novo Nordisk's case, that would currently equate to about $9.9 per share.

While Novo Nordisk's payout ratio might seem fairly standard, it's worth remembering that Novo Nordisk may be investing much of the rest of its net profits in future growth.

Novo Nordisk's most recent dividend payout was on 25 August 2024. The latest dividend was paid out to all shareholders who bought their stocks by 15 August 2024 (the "ex-dividend date").

Have Novo Nordisk's stocks ever split?

Novo Nordisk's stocks were split on a 2:1 basis on 19 September 2023 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk stocks – just the quantity. However, indirectly, the new 50% lower stock price could have impacted the market appetite for Novo Nordisk stocks, which in turn could have impacted Novo Nordisk's stock price.

Novo Nordisk stock price volatility

Over the last 12 months, Novo Nordisk's stocks have ranged in value from as little as $95.4789 up to $147.5933. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk's is 0.165. This would suggest that Novo Nordisk's stocks are less volatile than average (for this exchange).

Novo Nordisk overview

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Novo Nordisk is owned by insiders or institutions?
Currently 0.004% of Novo Nordisk stocks are held by insiders and 10.172% by institutions. How many people work for Novo Nordisk?
Latest data suggests 71,880 work at Novo Nordisk. When does the fiscal year end for Novo Nordisk?
Novo Nordisk's fiscal year ends in December. Where is Novo Nordisk based?
Novo Nordisk's address is: Novo Alle 1, Bagsvaerd, Denmark, 2880 What is Novo Nordisk's ISIN number?
Novo Nordisk's international securities identification number is: US6701002056 What is Novo Nordisk's CUSIP number?
Novo Nordisk's Committee on Uniform Securities Identification Procedures number is: 670100205

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.